Intestinal Behçet's disease: Maintenance of remission with adalimumab monotherapy

Inflammatory Bowel Diseases

Volumn 15, Issue 12, 2009, Pages 1769-1771

  Ariyachaipanich, Aekarach ^a   Berkelhammer, Charles ^a   Nicola, Haidy ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; INFLIXIMAB; PREDNISONE;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; BEHCET DISEASE; CASE REPORT; COLON ULCER; COLONOSCOPY; DIARRHEA; DRUG WITHDRAWAL; ENTEROPATHY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GENITAL ULCER; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; LETTER; MONOTHERAPY; MOUTH ULCER; PAPULAR RASH; PRIORITY JOURNAL; PUSTULE; REMISSION; TREATMENT DURATION;

ABDOMINAL PAIN; ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; BEHCET SYNDROME; CECAL DISEASES; FEMALE; HUMANS; SKIN DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 72549105127     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20869     Document Type: Letter

References (13)

1. Naganuma M, Sakuraba A, Hisamatsu T, et al. Efficacy of Infliximab for Induction and Maintenance of Remission in Intestinal Behçet's Disease. Inflamm Bowel Dis. 2008;14:1259-1264.
2. Lee JH, Kim TN, Choi ST, et al. Remission of intestinal Behçet's disease treated with antitumor necrosis factor alpha monoclonal antibody (infliximab). Korean J Intern Med. 2007;22:24-27.
3. Byeon JS, Choi EK, Heo NY, et al. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. Dis Colon Rectum. 2007;50:672-676.
4. Kram MT, May LD, Goodman S, et al. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum. 2003;46:118-121. (Pubitemid 36105841)
5. Hassard PV, Binder SW, Nelson V, et al. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behçet's disease: a case report. Gastroenterology. 2001;120:995-999. (Pubitemid 32193197)
6. Ju JH, Kwok SK, Seo SH, et al. Successful treatment of life-threatening intestinal ulcer in Behçet's disease with infliximab: rapid healing of Behçet's ulcer with infliximab. Clin Rheumatol. 2007;26:1383-1385.
7. Travis SP, Czajkowski M, McGovern DP, et al. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut. 2001;49:725-728. (Pubitemid 32989213)
8. Kim JS, Lim SH, Choi IJ, et al. Prediction of the clinical course of Behçet's colitis according to macroscopic classification by colonoscopy. Endoscopy. 2008;32:635-640.
9. Naganuma M, Iwao Y, Inoue N, et al. Analysis of clinical course and long-term prognosis of surgical and nonsurgical patients with intestinal Behçet's disease. Am J Gastroenterol. 2000;95:2848-2851. (Pubitemid 30783210)
10. Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behcet's disease: review and basis for recommendations. Rheumatology. 2007;46:736-741. (Pubitemid 47061701)
11. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol. 2005;32:98-105. (Pubitemid 40092599)
12. Estrach C, Mpofu S, Moots RJ. Behcet's syndrome: response to infliximab after failure of etanercept. Rheumatology. 2002;41:1213-1214. (Pubitemid 35203564)
13. van Laar JA, Missotten T, van Daele PL, et al. Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis. 2007;66:565-566. (Pubitemid 46580490)